These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8251356)

  • 1. A multicentre 12-week open study of a lipid-soluble folate antagonist, piritrexim in severe psoriasis.
    Perkins W; Williams RE; Vestey JP; Tidman MJ; Layton AM; Cunliffe WJ; Saihan EM; Klaber MR; Manna VK; Baker H
    Br J Dermatol; 1993 Nov; 129(5):584-9. PubMed ID: 8251356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of psoriasis with piritrexim, a lipid-soluble folate antagonist.
    Guzzo C; Benik K; Lazarus G; Johnson J; Weinstein G
    Arch Dermatol; 1991 Apr; 127(4):511-4. PubMed ID: 2006875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.
    Chládek J; Simková M; Vanecková J; Hroch M; Chládkova J; Martínková J; Vávrová J; Beránek M
    Eur J Clin Pharmacol; 2008 Apr; 64(4):347-55. PubMed ID: 18163165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial clinical studies of piritrexim.
    Laszlo J; Brenckman WD; Morgan E; Clendeninn NJ; Williams T; Currie V; Young C
    NCI Monogr; 1987; (5):121-5. PubMed ID: 3323908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma.
    Bleehen NM; Newman HV; Rampling RP; Ramsay JR; Roberts JT; Bedford P; Nethersell AB
    Br J Cancer; 1995 Sep; 72(3):766-8. PubMed ID: 7669591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
    Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT).
    Drach M; Papageorgiou K; Maul JT; Djamei V; Yawalkar N; Häusermann P; Anzengruber F; Navarini AA
    Arch Dermatol Res; 2019 Dec; 311(10):753-760. PubMed ID: 31396693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).
    Weiss GR; Sarosy GA; Shenkenberg TD; Williams T; Clendeninn NJ; Von Hoff DD; Woolley JL; Liao SH; Blum MR
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1867-73. PubMed ID: 2632268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.
    de Vries EG; Gietema JA; Workman P; Scott JE; Crawshaw A; Dobbs HJ; Dennis I; Mulder NH; Sleijfer DT; Willemse PH
    Br J Cancer; 1993 Sep; 68(3):641-4. PubMed ID: 8353055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral piritrexim, an effective treatment for metastatic urothelial cancer.
    de Wit R; Kaye SB; Roberts JT; Stoter G; Scott J; Verweij J
    Br J Cancer; 1993 Feb; 67(2):388-90. PubMed ID: 8431372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral piritrexim--a phase II study in patients with advanced soft tissue sarcoma.
    Schiesel JD; Carabasi M; Magill G; Casper E; Cheng E; Marks L; Feyzi J; Clendeninn NJ; Smalley RV
    Invest New Drugs; 1992 Jul; 10(2):97-8. PubMed ID: 1500271
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
    Dogra S; Krishna V; Kanwar AJ
    Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse in psoriasis with two different tapering regimens of methotrexate: a randomized open-label controlled study.
    Singh SK; Rai T
    Indian J Dermatol Venereol Leprol; 2015; 81(2):144-7. PubMed ID: 25751329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correct use of methotrexate].
    Verduijn MM; van den Bemt BJ; Dijkmans BA; van der Waal RI; Horikx A
    Ned Tijdschr Geneeskd; 2009; 153():A696. PubMed ID: 19785852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial.
    Radmanesh M; Rafiei B; Moosavi ZB; Sina N
    Int J Dermatol; 2011 Oct; 50(10):1291-3. PubMed ID: 21950300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study.
    Ranjan N; Sharma NL; Shanker V; Mahajan VK; Tegta GR
    J Dermatolog Treat; 2007; 18(5):295-300. PubMed ID: 17852635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
    Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of folate supplementation on methotrexate efficacy and toxicity in psoriasis patients and folic acid use by dermatologists in the USA.
    Al-Dabagh A; Davis SA; Kinney MA; Huang K; Feldman SR
    Am J Clin Dermatol; 2013 Jun; 14(3):155-61. PubMed ID: 23575550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.